Humira - Adalimumab - Dosage - Side Effects - Interactions - Warnings
Humira (adalimumab) drug information, dosage, side effects, drug interactions, and warnings. Humira, generic drug name adalimumab, is a TNF blocker drug classified as a biologic response modifier. Humira (adalimumab) is a human monoclonal antibody.
The Facts of Humira
Humira is one of the biologic response modifiers known as TNF blockers. Humira is prescribed to treat rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
Humira is one of the biologic response modifiers known as TNF blockers. Humira is prescribed to treat rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
TNF Blockers (Enbrel, Remicade, Humira) - Test Your Knowledge
How much do you know about rheumatoid arthritis drugs Enbrel, Remicade, and Humira? Take the quiz and test your knowledge.
How much do you know about rheumatoid arthritis drugs Enbrel, Remicade, and Humira? Take the quiz and test your knowledge.
Drug Monograph: Humira / Adalimumab
Adalimumab (Humira) is a recombinant human IgG1 monoclonal antibody. It is the second U.S. marketed monoclonal antibody specific for tumor necrosis factor-alpha (TNF-alpha). Adalimumab is given by subcutaneous injection.
Adalimumab (Humira) is a recombinant human IgG1 monoclonal antibody. It is the second U.S. marketed monoclonal antibody specific for tumor necrosis factor-alpha (TNF-alpha). Adalimumab is given by subcutaneous injection.
Patient Education: Humira / Adalimumab Injection
Patient education for Humira / adalimumab injection.
Patient education for Humira / adalimumab injection.
Monoclonal Antibody - What Is A Monoclonal Antibody?
Some of the newest biologic treatments for rheumatoid arthritis are monoclonal antibodies. What is a monoclonal antibody?
Some of the newest biologic treatments for rheumatoid arthritis are monoclonal antibodies. What is a monoclonal antibody?
Rheumatoid Arthritis Drugs Linked To Increased Risk of Infections And Cancer
TNF Blockers, specifically Humira and Remicade reportedly increase the risk of cancer and serious infection.
TNF Blockers, specifically Humira and Remicade reportedly increase the risk of cancer and serious infection.
When Is It Appropriate To Switch Your TNF Blocker Drug?
If an arthritis patient is on one of the TNF blocker drugs, when is it appropriate to switch to another? Is it possible for a patient to respond differently to another TNF blocker drug? Can a patient go back on one of the TNF blocker drugs after having stopped treatment?
If an arthritis patient is on one of the TNF blocker drugs, when is it appropriate to switch to another? Is it possible for a patient to respond differently to another TNF blocker drug? Can a patient go back on one of the TNF blocker drugs after having stopped treatment?
Biologic Drugs - Are Some Arthritis Patients Unsuitable Candidates For Biologic Drugs?
The medical history of some arthritis patients make them unsuitable candidates for biologic drugs such as Enbrel, Remicade, Humira, Orencia, and Rituxan.
The medical history of some arthritis patients make them unsuitable candidates for biologic drugs such as Enbrel, Remicade, Humira, Orencia, and Rituxan.
Enbrel, Remicade, and Humira - How are the drugs similar and different?
Patients are often advised to weigh the benefit and risk of any medication, including TNF blockers Enbrel, Remicade, and Humira. What similarities and differences are there between the three drugs?
Patients are often advised to weigh the benefit and risk of any medication, including TNF blockers Enbrel, Remicade, and Humira. What similarities and differences are there between the three drugs?
TNF Blocker Drugs and Infection Risk
TNF blocker drugs have an infection risk.
TNF blocker drugs have an infection risk.
Side Effects Of Enbrel, Remicade, and Humira - Weighing The Risk vs. Benefits
Arthritis patients sometimes fear the side effects of the TNF blockers Enbrel, Remicade, and Humira. Should they be afraid and avoid these drugs?
Arthritis patients sometimes fear the side effects of the TNF blockers Enbrel, Remicade, and Humira. Should they be afraid and avoid these drugs?
Early, Aggressive Arthritis Treatment For Newly Diagnosed Patients
Early, aggressive treatment for arthritis can prevent joint damage and deformity.
Early, aggressive treatment for arthritis can prevent joint damage and deformity.
Biologic Response Modifier: What is it?
Biological therapy, also referred to as immunotherapy or biotherapy, employ biologic response modifiers (BRMs) to stimulate or restore the ability of the immune system to fight disease and/or infection.
Biological therapy, also referred to as immunotherapy or biotherapy, employ biologic response modifiers (BRMs) to stimulate or restore the ability of the immune system to fight disease and/or infection.
06/28/2006 Humira History: Humira Pen Delivery Device FDA Approved
The Humira Pen, a new device for delivering Humira (adalimumab), has been approved by the FDA.
The Humira Pen, a new device for delivering Humira (adalimumab), has been approved by the FDA.
01/01/2006 Humira History: Humira & Methotrexate Better In Combination
01/01/2006, Results from the PREMIER study reveal that for adults with early, aggressive rheumatoid arthritis, treatment with Humira and methotrexate in combination is more effective than either drug alone.
01/01/2006, Results from the PREMIER study reveal that for adults with early, aggressive rheumatoid arthritis, treatment with Humira and methotrexate in combination is more effective than either drug alone.
10/06/2005 Humira History: Two New Indications Approved By FDA
10/06/2005, The FDA has approved two new indications for Humira. The newly approved indications for Humira are for first-line treatment of recent onset moderate to severe rheumatoid arthritis and for reducing signs and symptoms of active arthritis in patients with psoriatic arthritis.
10/06/2005, The FDA has approved two new indications for Humira. The newly approved indications for Humira are for first-line treatment of recent onset moderate to severe rheumatoid arthritis and for reducing signs and symptoms of active arthritis in patients with psoriatic arthritis.
08/12/2004 Humira History: FDA Expands Indication For Humira
08/12/2004, The U.S. Food and Drug Administration has approved an expanded indication for the rheumatoid arthritis treatment Humira, to include improvement in physical function for adult patients with moderately to severely active RA.
08/12/2004, The U.S. Food and Drug Administration has approved an expanded indication for the rheumatoid arthritis treatment Humira, to include improvement in physical function for adult patients with moderately to severely active RA.
08/05/2004 Humira History: CDC Reports TB Associated With TNF Blockers
08/05/2004, The FDA has determined that tuberculosis is a potential adverse reaction from treatment with the tumor necrosis factor-alpha antagonists Remicade, Enbrel, and Humira.
08/05/2004, The FDA has determined that tuberculosis is a potential adverse reaction from treatment with the tumor necrosis factor-alpha antagonists Remicade, Enbrel, and Humira.
03/07/2003 Humira History: FDA Panel Scrutinizes Safety Of 4 RA Drugs
03/07/2003, The risk versus benefit of Arava, Enbrel, Remicade, and Humira was reconsidered.
03/07/2003, The risk versus benefit of Arava, Enbrel, Remicade, and Humira was reconsidered.
12/31/2002 Humira History: Humira FDA Approved
12/31/2002, Humira is the first human monoclonal antibody approved for rheumatoid arthritis.
12/31/2002, Humira is the first human monoclonal antibody approved for rheumatoid arthritis.
10/15/2002 Humira History: Access To Therapy Initiated For Humira
10/15/2002, Humira (adalimumab) was made available to rheumatoid arthritis patients in need of other treatment options.
10/15/2002, Humira (adalimumab) was made available to rheumatoid arthritis patients in need of other treatment options.
06/24/2002 Humira History: Awaiting Approval Of Adalimumab (Humira)
06/24/2002, Abbott filed for regulatory approval of Humira (adalimumab).
06/24/2002, Abbott filed for regulatory approval of Humira (adalimumab).
06/30/2001 Humira History: Development Of Anti-TNF Drug Adalimumab
06/30/2001, Adalimumab (Humira) to be the first fully human anti-TNF therapy for rheumatoid arthritis.
06/30/2001, Adalimumab (Humira) to be the first fully human anti-TNF therapy for rheumatoid arthritis.
Patient Information: Humira (Adalimumab)
Patient information about Humira (Adalimumab), from Abbott.
Patient information about Humira (Adalimumab), from Abbott.